Amolyt Pharma, a global company specializing in developing therapeutic peptides for rare endocrine and related diseases, today announced that it will host a key opinion leader (KOL) webinar on AZP-3601, the Company’s lead product candidate for the potential treatment of hypoparathyroidism, on Friday, October 1, 2021 at 10:00 am ET.
